Chapter 7. Inhalation Anesthetics - PowerPoint PPT Presentation

1 / 69
About This Presentation
Title:

Chapter 7. Inhalation Anesthetics

Description:

R1 * Neuromuscular Produce adequate muscle relaxation & intubation of children Renal RBF slight Hepatic ... – PowerPoint PPT presentation

Number of Views:306
Avg rating:3.0/5.0
Slides: 70
Provided by: ocsu
Category:

less

Transcript and Presenter's Notes

Title: Chapter 7. Inhalation Anesthetics


1
Chapter 7. Inhalation Anesthetics
  • ?????
  • ???????
  • R1 ???

2
Inhalation anesthetics
  • Nitrous oxide, Chloroform and Ether.
  • Ethyl chloride, ethylene, cyclopropane
  • Methoxyflurane and Enflurane
  • Nitrous oxide, Halothane, Isoflurane, Desflurane,
    and Sevoflurane.

3
Inhalation anesthetics
  • The course of general anesthesia
  • 1) Induction
  • 2) Maintenance
  • 3) Emergence
  • Useful in the induction of pediatric patients
  • Adults prefer rapid induction with intravenous
    agents.

4
Inhalation anesthetics
  • Pharmacokinetics (how a body affects a drug)
  • Relationship between a drugs dose, tissue
    concentration, and elapsed time
  • Pharmacodynamics (how a drug affects a body)
  • The study of drug action, including toxic
    responses
  • MAC (Minimum alveolar concentration)
  • Clinical pharmacology of individual agents
  • Nitrous oxide, Halothane, Isoflurane,
    Desflurane, Sevoflurane

5
Pharmacokinetics
  • Mechanism of action of inhalation anesthetics
    remains unknown
  • Depends on attainment of a therapeutic tissue
    concentration in the central nervous system
  • There many steps, between the administration of
    an anesthetic from a vaporizer and its deposition
    in the brain

6
(No Transcript)
7
Pharmacokinetics Factors affecting inspiratory
concentration(FI )
  • Fresh gas flow rate (FGF rate)
  • Volume of the breathing system
  • (breathing circuit volume)
  • Any absorption by the machine or breathing
    circuit (circuit
    absorption)

8
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Uptake
  • Ventilation
  • Concentration

9
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Uptake
  • 1) FA/FI lt1.0
  • 2) Uptake ? ? Alveolar concentration ? ? FA/FI
    ?
  • 3) Gas concentration ? Partial pressure
  • Alveolar partial pressure
  • ? Anesthetic partial pressure in blood
  • ? Brain tissue concentration
  • 4) Uptake of Anesthetic agent ? ? Induction ?

10
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Anesthetic uptake factors
  • 1) Solubility in the blood
  • 2) Alveolar blood flow
  • 3) Difference in partial pressure between
    alveolar gas
  • and venous blood

11
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Solubility in the blood
  • 1) Solubility Insoluble agents(N2O) lt
    soluble agents(halothane)
  • FA Insoluble agents(N2O) gt soluble
    agents(halothane)
  • Induction speed Insoluble gt soluble
    agents
  • 2) Partition coefficients(?)
  • Relative solubility of an anesthetic
    in air, blood, and tissues
  • 3) Blood/gas partition coefficient? ?
    Solubility in Blood ? ?
  • Uptake ? ? Alveolar partial pr??
    induction speed ?

12
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Alveolar blood flow
  • 1) In the absence of pulmonary shunting ABF
    CO
  • CO? ? Uptake ? ? Alveolar partial pr??
    induction speed ?
  • 2) Insoluble agent
  • Alveolar blood flow ?? ??
  • 3) Soluble agent
  • Low CO ? Alveolar concentration ??
    overdosage

13
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Difference in partial pressure between alveolar
    gas and venous blood
  • 1) No tissue uptake ? Alveolar to venous
    partial pr difference 0
  • 2) Factors affecting tissue uptake
  • Tissue solubility of the agent(
    tissue/blood partition coefficient)
  • Tissue blood flow
  • Difference in partial pressure between
    arterial blood and the tissue

14
Pharmacokinetics Factors affecting alveolar
concentration(FA )
15
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • 4 group of tissue by solubility and blood flow
  • 1) Vessel-rich group
  • ex) brain, heart, liver, kidney,
    endocrine organ
  • 2) Muscle group
  • ex) skin, muscle
  • 3) Fat group
  • 4) Vessel-poor group
  • ex) bone, ligament, teeth, hair,
    cartilage

16
Pharmacokinetics Factors affecting alveolar
concentration(FA )
17
Pharmacokinetics Factors affecting alveolar
concentration(FA )
18
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Ventilation
  • Constantly replacing anesthetics taken up by
  • pul bloodstream ? FA/FI ? for soluble agent

19
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Concentration
  • 1) Concentration effect
  • Concentrating effect
  • Augmented inflow effect
  • 2) Second gas effect

20
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • (Anesthetic gas 50 uptake)
  • 10/9011
    40/6066
  • ? Concentrating effect

Gas 40
O2 20
Anesthetic gas 20
O2 80
Gas 10
O2 80
Anesthetic gas 80
O2 20
?
?
21
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • 1 of
    second gas 1 of
    second gas (1.7)



  • 1 of second gas









  • 0.4 of second gas




  • -

O2 19
N2O 80
O2 19(31.7)
N2O 40(66.7)
O2 19
N20 40
O2 7.6
N2O 32
22
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Alveolar partial pr gt Arterial partial pr
  • ?
    Alveolar-arterial difference
  • 1) Venous admixture
  • 2) Alveolar dead space
  •  
  • 3) Nonuniform alveolar gas distribution
  •  
  • 4) Ventilation/perfusion mismatch
  • (ex atelectasis,
    emphysema, neumonia)

23
Pharmacokinetics Factors affecting alveolar
concentration(FA )
  • Recovery from anesthesia
  • - Anesthetic concentration in brain
    tissue ?
  • Anesthetics can be eliminated by
  • 1) biotransformation
  • 2) transcutaneous
  • 3) exhalation

24
Pharmacokinetics Factors affecting elimination
  • Induction? ????? ???? Recovery? ??
  • Rebreathing
  • High Fresh gas flows
  • Low Anesthetic-circuit volume
  • Low absorption by the Anesthetic-circuit
  • Decreased Solubility
  • High CBF(Cerebral Blood Flow)
  • - Increased Ventilation

25
Pharmacokinetics Factors affecting elimination
  • Diffusion hypoxia
  • 1) Directly affect oxygenation by
    displacing O2
  • 2) diluting alveolar CO2 ? respiratory
    drive ?
  • ? prevent 100 O2 510min

26
PharmacodynamicsTheories of anesthetic action
  • Pharmacodynamics
  • the study of drug action, including toxic
    responses
  • how a drug affects a body
  • General anesthesia
  • reversible loss of consciousness
  • analgesia of the entire body
  • amnesia
  • muscle relaxation
  • General anesthesia agent
  • inert elements ( ex xenon )
  • simple inorganic compounds ( ex nitrous
    oxide)
  • halogenated hydrocarbons ( ex halothane )
  • complex organic structures (ex
    barbiturate )

27
PharmacodynamicsTheories of anesthetic action
  • Agent-specific theory  
  • Unitary hypothesis
  • Critical volume hypothesis
  • Fluidization theory of anesthesia
  • Lat phase separation theory

28
PharmacodynamicsMAC(Minimum alveolar
concentration)
  • Alveolar concentration that prevents movement in
    50 of patients in response to a standardized
    stimulation
  • MAC is useful measure
  • brain partial pressure ??
  • agents ??potency ??
  • experimental evaluation? ?? ??
  • The MAC value for different anesthetics are
    roughly additive
  • The same MAC ? CNS depression
  • ? Myocardial
    depression

29
PharmacodynamicsMAC(Minimum alveolar
concentration)
  • Point on dose-response curve
  • ? ED50,( median
    effective dose)
  • 1.3 MAC of any of the volatile anesthetics
    prevent movement in about 95 patients surgical
    incision
  • ? ED95
  • MAC Awake 0.3 0.4 MAC
  • One of the most striking is the 6 decrease in
    MAC per decade of age, regardless of volatile
    anesthetic
  • Unaffected by species, sex, or duration of
    anesthesia

30
PharmacodynamicsMAC(Minimum alveolar
concentration)
31
Nitrous oxidePhysical properties
  • ???? ??? ??? inorganic anesthetic gas
  • ??, ??
  • ??? ?, ??? ? ?? O2 ??? ??? ?? ??
  • ??, ????? gas??? ??, ?? ????? ????? ??? ??
  • ??? ??

32
Nitrous oxideEffect on organ system-
Cardiovascular
  • In vitro- stimulate the sympathetic nervous
    system in vitro, direct depression of
    myocardial contractility
  • In vivo- Stimulation of catecholamine
  • ? ABP, CO, HR Unchanged or
    slightly?
  • N2O? Myocardial depression? unmasked ?? ??
  • Coronary artery diseases
  • Severe hypovolemia
  • ? BP ? ? myocardial ischemia
  • Constriction pulmonary vascular smooth muscle
  • ? pulmonary
    vascular resistance ?
  • ? Rt.
    Ventricular end-diastolic pr. ?
  • Endogenous catecholamine level ?
  • ? epinephrine
    induced arrhythmia ?

33
Nitrous oxideEffect on organ system- Respiratory
  • CNS stimulation, pulmonary stretch receptor
    activation ? respiratory rate?(tachypnea) tidal
    volume?
  • net effect -gt minimal change in minute
    ventilation
  • and resting
    arterial CO2 level
  • Hypoxic drive?

34
Nitrous oxideEffect on organ system- Cerebral
  • Cerebral blood flow Cerebral blood volume?
  • ? Intracranial
    pressure mild?
  • CMOR2(Cerebral oxygen consumption)?
  • Levels of nitrous oxide below MAC provide
    analgesia in dental surgery and other minor
    procedures

35
Nitrous oxideEffect on organ system- Etc.
  • Neuromuscular
  • not provide significant muscle relaxation
  • not a triggering agent of malignant
    hyperthermia
  • Renal
  • Renal vascular resistance ? ? renal blood
    flow ?
  • glomerular filtration rate(GFR)
    urinary output ?
  • Hepatic
  • Hepatic blood flow ?
  • Gastrointestinal
  • Activation of the chemoreceptor trigger
    zone and the vomiting center in the medulla
  • ?Postoperative
    nausea vomiting

36
Nitrous oxide Biotransformation toxicity
  • Eliminated by exhalation almost
  • diffuses out
    through skin small amount
  • biotransformation
    than less 0.01
  • Vit B12??? cobalt ??? ???? ??
  • ? Vit B12 dependent enzyme ?
  • ?? Myelin??? ??? methionine synthetase
    ?
  • ? DNA??? ??? thymidylate
    synthetase ?
  • ? Prolonged exposure of anesthetic level
  • ?? Bone marrow depression(ex megaloblastic
    anemia )
  • ? Neurological deficiencies
  • (experipheral neuropathies and
    pernicious anemia)
  • Teratogenic effect
  • Polymorphonuclear leukocytes ?chemotaxis?
    motility? ?? ? immunological response change

37
Nitrous oxide Contraindication
  • Air embolism
  • Pneumothorax
  • Acute intestinal obstruction
  • Intracranial air ( ex dural closure or
    pneumoencephalus? ?? tension pneumocephalus)
  • Pul. air cyst
  • Intraocular air bubble
  • Tympanic membrane grafting
  • Pulmonary HTN patient

38
Nitrous oxide Drug interaction
  • MAC 105 vol
  • ? combination with the more potent
    volatile agent
  • Neuromuscular blockade?
  • (but effect N2Olt volatile agents)
  • Requirements of other agents?
  • Second gas effect

39
HalothanePhysical properties
  • Halogenated alkane
  • Nonexplosive
  • Nonflammable
  • Least expensive volatile anesthetics

40
HalothaneEffect on organ system- Cardiovascular
  • Dose-dependent reduction of arterial blood
    pressure
  • ? Myocardial
    depression (2.0MAC BP 50?)
  • Coronary artery vasodilator
  • But Systemic arterial pressure ? ?
    coronary blood flow ?
  • Hypotension ? Vagal stimulation ?, HR?
  • But this reflex?, sinoatrial node
    conduction slowing

  • ?Junctional rhythm and bradycardia
  • In infant HR? myocardial contratility?? CO?
  • Sensitize the heart to the arrhythmogenic effects
    to epinephrine
  • epinephrine 1.5µg/kg ?? ????

41
HalothaneEffect on organ system- Respiratory
  • Rapid, shallow breathing Not enough to counter
    TV?
  • ? alveolar ventilation?, resting PaCO2?
  • Cause of ventilatory effect
  • central mechanism (medullary depression)
  • peripheral mechanism (intercostal muscle
    dysfunction)
  • ? pre-existing lung disease
  • ? surgical stimulation
  • Hypoxic drive?
  • A potent bronchodilators
  • (? Airway reflex ?, bronchial smooth
    muscle ?? )
  • Mucociliary function ?
  • ? postoperative
    hypoxia atelectasis??

42
HalothaneEffect on organ system- Cerebral
  • Cerebral vessels dilating
  • ? cerebral vascular resistance? ,
    CBF ?
  • Autoregulation (Arterial blood pressure? ????
    CBF? ???? ??) ? Intracranial pressure?
  • Prevent Hyperventilation

43
HalothaneEffect on organ system- Etc.
  • Neuromuscular
  • Skeletal muscle relaxation
  • Non-depolarizing neuromuscular-blocking
    agents (NMBA) effect?
  • Malignant hyperthermia
  • Renal
  • Renal blood flow, GFR(glomelular filtration
    rate), urinary output ?
  • (? Arterial blood pressure cardiac
    output ?)
  • GFR? lt Renal blood flow? ? Filtration
    fraction?
  • Prevent Preoperative hydration
  • Hepatic
  • CO? ? hepatic blood flow?
  • Hepatic artery vasospasm
  • The metabolism and clearance of Fentanyl,
    phenytoin, verapamil?

44
Halothane Biotransformation toxicity
  • Be oxidized in the liver by a cytochrome P450
    (2EI)

  • ?
    trifluoroacetic acid

  • Inhibited by pretreatment with
    disulfiram
  • viral hepatitis, impaired hepatic perfusion,
    hepatocyte hypoxia, sepsis, hemolysis, benign
    postoperative intrahepatic cholestasis, drug
    induced hepatitis ? postoperative hepatic
    dysfunction
  • Halothane hepatitis is extremely rare (1/35000 )
  • - Hepatitis is increased risk at
  • halothane ??? ??
    ???? ?? ?? ??
  • ??? ??? ??
  • Halothane ???
    ??? ???? ?? ??
  • ????? halothane
    ??? ?? Hx()? ??

45
Halothane Contraindication
  • Halothane? ??? ???? ?? ?? ? ??? ???? ? ?? ??? ??
    ?
  • Intracranial mass lesion ? Intracranial
    hypertension
  • Hypovolemic pt.
  • Severe cardiac disease ( ex aortic stenosis )
  • Epinephrine? ???? ??? ??
  • Pheochromocytoma

46
Halothane Drug interaction
  • ß- adrenergic blocking agent (propranolol),
  • Ca channel blocking agent (verapamil)

  • ? Myocardial depression?
  • Tricyclic antidepressants, MAO inhibitor
  • ? fluctuations in blood
    pressure arrhythmias
  • ( but not
    absolute contraindication)
  • Aminophylline ? Severe ventricular arrhythmias

47
Isoflurane Physical properties
  • Nonflammable volatile anesthetic
  • Pungent ethereal oder
  • Chemical isomer of enflurane
  • but different physiochemical property

48
Isoflurane Effects on organ system-
Cardiovascular
  • Minimal cardiac depression
  • but carotid baroreflex ? HR??
    CO??
  • ß-adrenergic stimulation
  • ? skeletal muscle blood flow?
  • systemic vascular
    resistance?
  • arterial blood pressure ?
  • Isoflurane??? ??? ??
  • ? HR ?, arterial blood
    pressure?,
  • norepinephrine? plasma
    level?
  • Dilates coronary arteries

49
Isoflurane Effects on organ system- Respiratory
  • Respiratory depression, Tachypnea ( less
    pronounced)
  • ? minute ventilation?(
    more pronounced)
  • 0.1MAC?? ??? Isoflurane? hypoxia?
  • hypercapnia? ?? ???? ?? ??? ????
  • Good bronchodilator

50
Isoflurane Effects on organ system- Cerebral
  • gt1.0 MAC CBF intracranial pressure?
  • but Isoflurane lt Halothane
  • Reversed by hyperventilation
  • Cerebral metabolic oxygen requirement?
  • 2.0 MAC
  • ? electrically silent
    electroencephalogram(EEG)
  • EEG suppression
  • ? cerebral ischemia?
    brain protection

51
Isoflurane Effects on organ system- Etc.
  • Neuromuscular
  • Relax skeletal muscles
  • Renal
  • Renal blood flow ?, glomerular filtration rate
    ? ,
  • urinary output ?
  • Hepatic
  • Total hepatic flow ?
  • Hepatic oxygen supply better maintained than
    with Halothane

52
Isoflurane Biotransformation toxicity
  • Trifluoroacetic acid? ??
  • Serum fluoride fluid levels may rise
  • But no nephrotoxicity

53
Isoflurane Contraindication
  • No unique contraindication

54
Isoflurane Drug interaction
  • Safe dose of Epinephrine up to 4.5 µg/kg
  • NMBAs effect?

55
Desflurane Physical properties
  • Isoflurane? ?? ??? ??
  • High vapor pressure ? special vapor
  • Low solubility in blood and body tissues
  • ? Ultrashort duration
  • ? Very rapid wash in and wash out
    of anesthetic
  • Moderate potency

56
Desflurane Effects on organ system-
Cardiovascular
  • Similar to isoflurane
  • Dose?? systemic vascular resistance? ? arterial
    blood pressure ?
  • CO unchanged or mild?(12 MAC)
  • Heart rate, central venous pressure, pulmonary
    artery pressure moderate?
  • Cardiovascular disease ? desflurane concentration
    rapid?? heart rate, BP, catecholamine level
    worrisome?
  • Attenuated by fentanyl, esmolol, clonidine
  • coronary blood flow unchanged

57
Desflurane Effects on organ system- Respiratory
  • TV ? RR ?
  • Alveolar ventilation ? ? resting PaCO 2 ?
  • Ventilatory response ?
  • Pungency and airway irritation during induction
  • ? salivation, breath-holding, coughing,
    laryngospasm

58
Desflurane Effects on organ system- Cerebral
  • Similar to Isoflurane
  • Directly vasodilates the cerebral vasculature

  • ? CBF ?, ICP?
  • Cerebral metabolic rate of oxygen(CMRO2) ?
  • ? cerebral
    vasoconstriction CBF?
  • Cerebral oxygen consumption ?
  • ?During periods of desflurane-induced
    hypotension,
  • CBF is adequate to maintain
    aerobic metabolism

59
Desflurane Effects on organ system- Etc.
  • Neuromuscular
  • dose-dependent of TOF ?? ???????
  • Renal
  • No evidence of any nephrotoxic effects
  • Hepatic
  • No evidence of hepatic injury

60
Desflurane Biotransformation toxicity
  • Minimal metabolism
  • Insignificant percutaneous loss
  • CO poisoning(by carbon dioxide absorbent)
  • disposing of dried out
    absorbent or use of calcium hydroxide ? minimize
    the risk

61
Desflurane Contraindication
  • Severe hypovolemia
  • Malignant hyperthermia
  • Intracranial hypertension

62
Desflurane Drug interaction
  • Potentiates nondepolarizing neuromuscular
    blocking agents
  • Safe dose of Epinephrine Up to 45 µg/kg
  • Associated with delirium in some pediatric
    patients

63
Sevoflurane Physical properties
  • Nonpungency rapid increase in alveolar
    anesthetic concentration
  • ? Smooth rapid
    inhalation induction
  • Rapid emergence than Isoflurane
  • Faster emergence
  • ? Greater incidence of delirium in some
    pediatric patients
  • treated with 1.02.0 µg/kg
    of fentanyl

64
Sevoflurane Effects on organ system-
Cardiovascular respiratory
  • Cardiovascular
  • Depresses myocardial contractility.
  • Systemic vascular resistance arterial
    blood pr. ?
  • Prolong the QT interval
  • Respiratory
  • Depresses respiration
  • Reverse bronchospasm

65
Sevoflurane Effects on organ system- Cerebral
  • CBF, ICP slight?
  • gt1.5 MAC ? impair autoregulation of CBF
  • ? CBF ? during hemorrhagic
    hypotension
  • Cerebral metabolic oxygen requirement?

66
Sevoflurane Effects on organ system- Etc.
  • Neuromuscular
  • Produce adequate muscle relaxation
    intubation of children
  • Renal
  • RBF slight?
  • Hepatic
  • Portal vein blood flow? but hepatic artery
    blood flow? ? Maintain total hepatic blood flow
    oxygen delivery

67
Sevoflurane Biotransformation toxicity
  • Liver microsomal enzyme P-450(2E1)? ?? ??
  • ? Inorganic fluoride nephrotoxicity
  • but clinically
    associated with significant renal dysfunction
  • By Alkali ( Barium hydroxide lime or soda lime )
  • Sevoflurane ? Nephrotoxic end product
  • ( Compound A,
    fluorometal-2, 2-difluoro-1-vinylether )
  • Compound A? ?? ??? ????? ??
  • Respiratory gas temperature?
  • Low-flow anesthesia
  • Dry barium hydroxide absorbent (Baralyme)
  • Sevoflurane concentration?
  • Anesthetic of long duration
  • Hydrogen fluoride ? acid burn on respiratory
    mucosa

68
Sevoflurane Contraindication
  • Severe hypovolemia
  • Malignant hyperthermia
  • Intracranial hypertension

69
Sevoflurane Drug interaction
  • Potentiates NMBAs
  • Catecholamine-induced arrhythmia???? ??
Write a Comment
User Comments (0)
About PowerShow.com